Research Topics
| Gianni BonadonnaSummaryAffiliation: Istituto Nazionale Tumori Country: Italy Publications
| Collaborators
|
Detail Information
Publications
The contribution of Gianni Bonadonna to the history of chemotherapyDomenico Ribatti
Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G Cesare, 11, Policlinico, 70124 Bari, Italy
Cancer Chemother Pharmacol 60:309-12. 2007..This review article summarizes the seminal work of the Italian scientist Gianni Bonadonna on the treatment of breast cancer and Hodgkin's disease.- ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term resultsGianni Bonadonna
Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
J Clin Oncol 22:2835-41. 2004..Combined-modality approaches improved results compared with RT, but the optimal extent of RT fields when combined with chemotherapy warranted additional evaluation... - Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancerGianni Bonadonna
Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
J Clin Oncol 22:1614-20. 2004..To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse... - 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyGianni Bonadonna
Istituto Nazionale Tumori, 20133 Milan, Italy
BMJ 330:217. 2005.... - Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer InstituteGianni Bonadonna
Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
Eur J Cancer 41:998-1006. 2005..The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors... - HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancerAngela Moliterni
Medical Oncology Unit, Department of Experimental Oncology, Scientific Direction, Istituto Nazionale Tumori, Italy
J Clin Oncol 21:458-62. 2003..The effect of treatment was more evident on OS in HER2+ patients (HR = 0.61; CI, 0.32 to 1.16) than in HER2- patients (HR = 1.26). CONCLUSION: Our data indicate that adding ADM to CMF might be beneficial for patients with HER2+ tumors... - Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyLuca Gianni
Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
Clin Cancer Res 11:8715-21. 2005..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate... - Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrenceRomano Demicheli
Department of Medical Oncology, IRCCS Foundation, National Cancer Institute, Milan, Italy
Cancer Sci 101:826-30. 2010.... - Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumourRomano Demicheli
Istituto Nazionale Tumori, Milano, Italy
Breast Cancer Res 6:R689-96. 2004..Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence... - Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trialLisa Licitra
Istituto Nazionale Tumori, Milan, Italy
J Clin Oncol 21:327-33. 2003..Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity... - Comment to Jatoi et al. reportRomano Demicheli
Department of Medical Oncology, Instituto Nazionale Tumori, Milano 20132, Italy
Breast Cancer Res Treat 93:1-2. 2005 - Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
J Clin Oncol 27:2474-81. 2009..To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy... - Breast cancerPinuccia Valagussa
Istituto Nazionale Tumori, Milano, Italy
Cancer Chemother Biol Response Modif 21:585-608. 2003 - Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screeningRomano Demicheli
Istituto Nazionale Tumori, Department of Medical Oncology, Via Venezian 1, 20137 Milan, Italy
J Clin Oncol 22:102-7. 2004..To provide data relevant to the paradoxical mortality excess for women age 40 to 49 years observed during the first 6 to 8 years in the invited group in all mammography screening studies... - Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patientsMichael Retsky
Department of Surgical Research, Children s Hospital and Harvard Medical School, Boston, MA, USA
Breast Cancer Res 6:R372-4. 2004..We could imagine that it also plays a role in adjuvant chemotherapy effectiveness since, perhaps not coincidentally, this is most beneficial for premenopausal node-positive patients... - CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis
Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:1278-87. 2002..CONCLUSION: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens... - Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancerGianni Bonadonna
Department of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori [corrected
J Clin Oncol 26:342-4. 2008 - Comment to "Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and intact primary tumor" by G V Babiera, R Rao, L Feng, F Meric-Bernstam, H M Kuerer, S E Singletary, K K Hunt, M I Ross, K M Gwyn, B W Romano Demicheli
Ann Surg Oncol 14:1519-20. 2007 - Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005Romano Demicheli
Breast Cancer Res Treat 97:341-3. 2006 - Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagusPaolo Bidoli
Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Cancer 94:352-61. 2002..The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma... - BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimensGeorge Z Rassidakis
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Blood 100:3935-41. 2002..We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens... - Refined measurement of outcome for adjuvant breast carcinoma therapyJohn W Gamel
Veterans Affairs Medical Center, Louisville, Kentucky, USA
Cancer 97:1139-46. 2003..This deficiency makes it difficult to determine the long-term difference in impact between the two treatment arms of a clinical trial... - Breast cancerPinuccia Valagussa
Istituto Nazionale Tumori via Venezian 1 20133 Milan Italy
Cancer Chemother Biol Response Modif 20:493-517. 2002 - Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapyCarlo Visco
Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, USA
Leuk Lymphoma 45:2085-92. 2004..0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT... - Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcomeMarco Herling
Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:2114-20. 2003..CONCLUSIONS: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients... - BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcomeGeorge Z Rassidakis
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 8:488-93. 2002..Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD...